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Introduction 
Since the initial disclosure of its moderate cytoxicity to Ehrlich 
ascites tumour cells,[1]  the complex Cp2TiCl2 (Cp = -C5H5) (1) 
and its derivatives have attracted considerable attention, in part, 
due to their potential against tumour types resistant to existing 
treatments (especially cisplatin). As the biological activity of 1 has 
proved too low for clinical use,[2] numerous studies have targeted 
the structural modifications summarised in Scheme 1 in a quest for 
compounds with greater potency (lower IC50 or GI50 values).
[3] 
These modifications, reported by Tacke and others, have resulted 
in the identification of the compounds 2-4 and 5 (so called 
‘Titanocene-Y’) as the current ‘optimal’ structures - delivering IC50 
values in the range 5.5-28 m against an identical pig kidney 
tumour LLC-PK cell line (thus allowing direct comparison). The 
secondary centres in 2-3 and the proximal oxygen of 4 suggested to 
us that species containing (-C5H4CHR(2-MeOPh)) units might be 
good candidates for therapeutic screening. However, these are 
notably absent in the current titanocene dichloride compound 
library. A closer look at the literature reveals that additions of RLi 
or RMgX to 6-substituted pentafulvenes (the normal optimal route) 
suffer badly from competing hydride transfer (unless R = Me or 
Ar).[3] This synthetic deficiency has left the –CHAlkylAr motif 
rather underrepresented in substituted cyclopentadienyl chemistry, 
where aside from any biological use, wide ranges of additional 
applications in organic synthesis and catalysis have also been 
identified.[4]  
Based on our experiences,[5] we speculated that hydride transfer 
would be avoided if a ‘Michael-like’ organocopper addition giving 
A was employed (Scheme 2). Cyclopentadienyl groups are widely 
regarded as ‘non transferable’ from transition metals, but CpCuI 
complexes are some of the most labile known.[6] We reasoned that 
with a suitable nucleophilic terminal organometallic it should 
prove possible to close the catalytic cycle of Scheme 2.  
 
  
Scheme 1. Lead and titanocene structural optimisation. Biological activities 
against identical pig kidney cancer LLC-PK cells; for which cisplatin gives 
an IC50 value of 3.3 m. In this paper GI50 values are used –  the 
concentration which inhibits cell proliferation by 50%. 
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Scheme 2. Proposed use of fulvenes substrates in copper-catalysed addition 
of terminal organometallics. 
Thus, our targets became: (i) defining the new catalysis of 
Scheme 2; and (ii) carrying out screening for the derived 
titanocenes in human carcinoma cell lines. 
Results and Discussion 
Synthesis 
1-(Cyclopenta-2,4-dien-1-ylidenemethyl)2-methoxybenzene (6) 
was selected for our trials and prepared by literature procedures 
from cyclopentadiene and 2-MeO(C6H4)CHO.
[7] Initial addition of 
6 to a 5-fold excess of a stoichiometric cuprate prepared from 
CuI/LiBr/EtMgBr in THF at -10 oC showed the ethyl addition 
product 7a in modest yield (43%) after 16 h at -10 oC; but with  no 
detectable hydride transfer by-products. In particular, two 
overlapping multiplets at H 1.81-2.08 confirmed the presence of 
diastereotopic methylene groups from the ethyl addition. 
Additionally, two broadened signals at H 2.85 and 3.00 in a 0.8 
H:1.2 H ratio indicated the presence of two [1,5] hydrogen shift 
tautomers where the CH2 is either  or  to the ipso-
cyclopentadienyl carbon. Through 2D (COSY, HMQC and 
HMBC) near full assignment of the two sets of tautomeric signals 
could be made, however, they could not be independently 
distinguished. Next attention was focussed on attaining a viable 
catalytic system. Base reaction conditions of -10 oC and 16 h with 
2.5 equivalents of RMgBr were selected and the other reaction 
components varied (Table 1). 
Table 1. Development of catalytic procedure for RMgBr additions to 
fulvene (6).[a] 
 
 
Run CuI (mol-%) Additive 
(mol-%) 
R Solvent Yield/% 
1 CuCN 
(10) 
LiCl 
(10) 
Et 
(7a) 
THF 88 
2 CuBr•SMe2 
(10) 
- Et 
(7a) 
THF 85 
3 CuBr•SMe2 
(10) 
- nBu[b] 
(7b) 
THF 87 
4 CuBr•SMe2 
(10) 
- iBu 
(7c) 
THF 92 
5 CuBr•SMe2 
(10) 
- allyl 
(7d) 
THF 91 
6 CuBr•SMe2 
(10) 
- Me 
(7e) 
THF 27[c] 
7 CuBr•SMe2 
(10) 
- Ph 
(7f) 
THF 24[c] 
8 CuI 
(8) 
PPh3 
(10) 
Me 
(7e) 
tBuOMe 91[d] 
9 CuI 
(8) 
PPh3 
(10) 
Ph 
(7f) 
tBuOMe 66 
[a] Carried out from 6 on a 1-10 mmol scale, isolated yields except were 
noted. [b] nBuMgCl used. [c] Conversion of 6. [d] Isolated yield from 77% 
conversion (10 mmol scale). 
As copper(I) cynanide is known to result in highly reactive 
cuprates[8] it was selected for an initial trial and provided a high 
yield of 7a at 10 mol-% (run 1). Either no reactions at all with 
EtMgBr (or slow and unclean transformations under other 
promotions) were observed in the absence of CuI under the 
conditions tried. Due to practical considerations (cyanide waste and 
the need to dry LiCl) we sought an alternative to CuCN and were 
delighted to find that, for a range of Grignards (runs 2-5), 
essentially quantitative conversion of 6 (>95%) could be attained 
and high yields of the cyclopentadiene products 7 isolated using 
simple commercial CuBr•SMe2. These runs could be conducted on 
at least 2 g scale without diminuation of yields. One limitation of 
the CuBr•SMe2 catalyst system was that it would not provide the 
methyl and phenyl derivatives (7e-f) in good yield – only partial 
conversions were attained (runs 6-7). These deficiencies could be 
overcome through the use of tBuOMe (MTBE) and PPh3 (runs 8-9). 
Presumably the lower coordination ability of MTBE leads to a 
more Lewis acidic cuprate that can overcome slower 
transmetallation rates from these Grignard reagents from ‘CpCuI’ 
(A) Scheme 2. Some support is given to this idea by the 
observation that MeMgBr (Mg-C 60 kcal mol-1)[9] is the slowest 
reacting system and the only one that does not give complete 
conversion (ca. 80±5% depending on the reaction scale). We were 
interested to probe if the crucial phosphine in these systems is able 
to deliver ligand accelerated catalysis – and thus, potentially an 
asymmetric synthesis. Screening of a small library of chiral 
phosphines provided no evidence of any induced stereoselectivity 
in the addition of EtMgBr to 6 under any of the conditions we tried. 
We conclude that while the added PPh3 in runs 8-9 plays a cuprate 
stabilising role it is not critically involved in the addition transition 
state. All of the isolated cyclopentadiene products (7) are 
colourless oils and show the expected spectroscopic properties. All 
are isolated as close to a 1:1 mixture of : [1,5] hydrogen shift 
tautomers. 
With an efficient route to 7 in hand attention was focused on the 
preparation of the derived titanocenes. Rapid quantatitive 
deprotonation of 7a by nBuLi (1.1 equiv.) in THF, Et2O or MTBE 
at 0 oC was confirmed by D2O quench leading to d1-7a as an / 
isomer mix (Scheme 2). Direct use of these reaction mixtures with 
either TiCl4 or TiCl4(THF)2 led only to intractable mixtures. As has 
been found before[3] filtration and drying of the intermediate 
organolithium species 8 is required in order to attain 
chemoselective preparation of the titanocene dichlorides (9). 
Presently the nature of the impurity(ies) in the crude deprotonation 
mixture that causes these issues is unknown. The lower yield of 8b 
is caused by its higher solubility in hydrocarbons containing trace 
t-BuOMe. Recrystallisation of the crude titanocene reaction 
mixtures containing 9 allowed the isolation of analytically pure 
red-orange/brown powders containing a 1:1 mixture of rac:meso 
diastereomers for 9a-e from CH2Cl2-pentane. The 
1H NMR 
spectrum of the rac and meso-9a is representative of the class. A 
triplet at H 0.76 is due to the methyl group of one diastereomer 
and shows a typical 3JHH of 7.5 Hz. This signal is overlapped by 
the equivalent methyl of the other diastereomer at H 0.77.  A 
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broad signal at H 1.96 and an associated multiplet 2.08-2.23 
(integrating to 4 H) are assigned to the overlapping diastereomeric 
signals of the CH2 groups while the methoxy and -CH groups of 
the two stereoisomers are coincident at H
 3.78 and 4.42 
respectively. The broadness of the latter indicates restricted 
rotation within the molecule – most likely about the Cp-CHEtAr 
bond. The chemical shift region between 5.97 to 6.73 ppm contains 
two sets of diastereotopic cyclopentadienyl methine protons. The 
1H:1H COSY spectrum of the aromatic region (see Supporting 
Data) allows assignment of two sets of four mangnetically 
inequivalent protons (H 5.97, 6.06, 6.46, 6.73 and H 6.01, 6.17, 
6.40 and 6.71) for the C5H4R units of the two diastereomers. The 
phenylene signals are badly overlapped with only slight separation 
on the H-C(4) Ar (δH 7.22 and 7.23) and H-C(5) Ar (δH 6.90 and 
6.91) signals of the diastereomers. The rac/meso signals of H-C(3) 
Ar at 6.91 ppm and H-C(6) Ar at 7.04 ppm are essentially 
coincident with the latter signal being appreciably broadened at 
ambient temperature. 
   
Scheme 3. Preparation of titanocene dichlorides (9). 
In the case of 9f only small initial crops of crystalline rac-9f 
were isolated from CHCl3-hexane, and the meso form could not be 
isolated in a pure form from the mother liquors (which provided 
only sticky intractable rac/meso mixtures). The relative rac 
stereochemistry of 9f could be confirmed by X-ray crystallography 
(Figure 1). The Ti-Cl and Ti-C(Cpave) distances in rac-(9f) at 2.335 
and 2.392 Å respectively compare well with typical titanocene 
dichloride structures in the Cambridge Crystallographic Database 
bearing a Cp-CHAr unit.[10] These mono substituted titanocene 
dichlorides show Ti-Cl and Ti-C(Cpave) ranges of 2.31-2.37 and 
2.39-2.45 Å respectively. Often the Ti-C distance associated with 
the point of substitution in such complexes is appreciably 
lengthened (2.40-2.49 Å) and this is the case in rac-(9f) which 
shows 2.442 Å for Ti-C(1). The exact mode of anti cancer 
therapeutic action of such complexes is not completely understood 
– but labilisation of both the Ti-Cl and Ti-Cp ligands has been 
postulated.[2] It is unknown if steric factors are involved in such 
processes, if they occur, but clearly such effects are present in 9f. 
The origin of the restricted rotation in the complexes 9 is also clear 
from the structure of rac-(9f) were the C(2)-C(7) 3.28 Å and C(5)-
C(15) 3.00  Å distances are close to the expected C…C van der 
Waals contact ranges. 
 
Figure 1. Molecular structure of rac-9f. 
 
Growth inhibitory studies 
The antiproliferative activities of the RCHAr-substituted 
titanocenes (9) in comparison to the simple benzyl-substituted 
titanocene analogue (10)[11], titanocene dichloride (1) (Scheme 4) 
and cisplatin, cis-PtCl2(NH3)2, were evaluated in vitro against 
HCT-116 (colo-rectal), MiaPaCa-2 (pancreatic), and MDA-468 
(triple negative breast) carcinoma cell lines, representing 
intractable cancers from three different organ sites. Breast cancer is 
the most common cancer among women (1.38 million new cases 
worldwide in 2008), and the second most commonly diagnosed 
cancer overall – 23% of all cancers dignosed in 2008 were breast 
cancer.[12a] Triple negative (basal-like) breast cancer i.e. those 
which do not express oestrogen receptor, progesterone receptor or 
human epidermal growth factor 2, tends to affect younger women, 
is aggressive, more resistant to therapy and associated with poor 
prognoses.[12b] Colo-rectal carcinoma is the third most common 
cancer and caused >600000 deaths globally in 2008.[12a] Pancreatic 
carcinoma is particularly resistant to chemotherapy, often 
diagnosed with metastatic disease, and an appalling 5 year survival 
rate (<5%). Thus, development of new therapies for such malignant 
diseases represents a currently severely unmet need. 
 
Scheme 4. Species compared in growth inhibitory studies against cisplatin, 
cis-Cl2Pt(NH)3. 
Compound concentrations which inhibit cell growth by 50%  
(GI50 values) after 72 h exposure of cells to agents 9,  10 and 1, 
were obtained by standard MTT [3-(4, 5-dimethyl-thiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay and are represented in 
Table 2. Compound stocks (10 mM) were prepared in DMSO and 
diluted in nutrient medium immediately prior to use. All of the 
complexes 9 were assayed as 1:1 rac/meso mixtures of 
stereoisomers except for 9f which was a single rac diastereomer. 
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As can be deduced from Table 2, all chiral-substituted 
titanocenes (9) are active against all the studied cancer cell lines in 
the examined concentration range (0.01 µM - 100 µM). Dose-
response relationships of (9a) and (9e) in HCT-116, MiaPaCa-2 
and MDA-468 carcinoma cell lines are highlighted in Figure 3. 
Table 2. Growth inhibitory assays. GI50 values are represented as 
mean ± SEM of three independent experiments (n = 4 per 
experiment).   
  Mean GI50 (µM) 
Compound HCT-116 MiaPaCa-2 MDA-468 
(9a) 7.7 ± 1.4 5.8 ± 2.3 2.3 ± 0.8 
(9b) 42.4 ± 4.8 34.7 ± 3.1 14.6 ± 4.2 
(9c) 24.6 ± 3.5 22.4 ± 3.9 32.3 ± 1.7 
(9d) 28.6 ± 2.9 24.8 ± 1.0 26.7 ± 0.5 
(9e) 5.7 ± 2.8 6.6 ± 1.0 7.7± 2.6 
rac-(9f) 25.0 ± 0.5 11.4 ± 2.6 27.5 ± 0.5 
(10) 73.4 ± 3.9 22.7 ± 1.5 76.2 ± 2.6 
(1) >100 >100 >100 
cisplatin 6.9 ± 0.1 6.8 ± 2.4 0.6 ± 0.1 
 
Duplicate DMSO (vehicle) controls were carried out on all three 
cell lines representative of DMSO content over the whole range of 
concentrations; growth of cells was not significantly inhibited  
(DMSO ≤ 1%). On direct comparison of 9 with 1 and 10, it can be 
deduced that all chiral complexes 9 are much more active than their 
titanocene reference counterparts. Of particular note are 9a, and 9e 
with GI50 values < 10 µM in all 3 cell lines – making them some of 
the most active titanocenes reported in this area, and directly 
comparable to cisplatin (particularly against HCT-116 and 
MiaPaCa-2 cells). This can be attributed to the presence of their -
CHRAr substituents, which might lead to a significant increase in 
inhibitory activity – as has been seen before.[3]. MDA 468 
demonstrates greater sensitivity towards 9a, 9b and cisplatin. 
MiaPaCa-2 is more (reltively) sensitive to the growth inhibitory 
properties of rac-9f and 10. Titanocenes 9d and 9e demonstrate 
approximately equiactivity in all 3 cell lines.  In an in vitro 
cytotoxicity study carried out on benzyl-substituted titanocenes 
such as 5 against 36 human tumour cell lines from 14 different 
organ sites it was found that the cytotoxicity of 5 relative to 
cisplatin was comparatively much lower in colon carcinoma cell 
lines whilst comparable in pancreas and breast carcinoma cell 
lines.[13]  
  Of particular note is the chain length effect on the cytoxicity of 
family (9), it can be seen in Table 2 and Figure 3 that the longer the 
chain length, the lower the cytoxicity values obtained. As the chain 
length increases the cytotoxicity diminishes by a faction of ca. 6 
from a C1-C2 side chain to a n-butyl chain. Best results were 
obtained for titanocenes with ethyl side chain (9a) showing GI50 
values of 7.7 µM for HCT-116, 5.8 µM for MiaPaCa-2 and 2.3µM 
for MDA-468 or methyl side chain (9e) with GI50 values of 5.7 µM 
for HCT-116, 6.6 µM for MiaPaCa-2 and 7.7 µM for MDA-468 
These two titanocenes show almost identical activity with uniform 
growth inhibitory responses in all three cancer cell lines that are 
similar to standard cisplatin (which shows GI50 values of 6.9 µM 
for HCT-116, 6.8 µM for MiaPaCa-2 and 0.6 µM for MDA-468). 
Compounds 9a and 9e are are equiactive to cisplatin based on an 
unpaired t-test (P < 0.01),[14] except for 9e vs. cisplatin in MDA-
468 (where cisplatin is significantly more active). 
The growth inhibitory range shown by the n- and i-butyl 
derivatives (9c-d) across HCT-116 and MDA-468 cell lines 
deserves comment. Complex 9c is statistially (unpaired t-test – P < 
0.01) less active towards HCT-116 than MDA-468, while for 9d, 
the trend is reversed. It has been proposed[2] that the 
cyclopentadienyl ligands are removed in the cytotoxic events 
acssociated with Cp2TiCl2 theraputics; limiting the role of the 
cyclopentadienyl ligand to modulating drug uptake into the cell. 
The activity profile of 9c-d is therefore somewhat unexpected in 
the light the rather close structural similarity of these complexes. 
This might  hint at significant molecular recognition at some point 
in the mode of action rather than simple pharmokinetic affects. 
Finally, we note also significantly increased growth inhibition 
evoked by the class 9, compared to titanocene-Y 5, in colon 
carcinoma cell lines.[13]   
Conclusion 
Through use of copper-catalysis the additions or alkyl Grignard 
reagents to pentafulvene acceptors becomes a practical process 
without competing hydride transfer. The resultant cyclopentadienyl 
ligands are readily complexed to TiCl4 and the resulting substituted 
(-C5H4CHRAr)2TiCl2 (R = alkyl) (9) are some of the most 
cytotoxic agents that have been found in this area. As the 
cyclopentadienes 7 are prepared in racemic form the complexes 9 
are attained as rac/meso mixtures of diastereomers. In principle, 
organometallic reagents in the presence of chiral additives (e.g. (-)-
sparteine) offer the possibility to access enantioenriched samples of 
7 and hence 9. This approach is now being actively targeted in our 
laboratory as screening individual stereoisomeric forms of 9 is 
likely to be a useful tool in identifying the biological mode of 
action of these titanocene dichlorides.  
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 Figure 3. MTT assay profiles for (9a) and (9e) on MIAPACA-2, HCT-116 and MDA-468 growth. 
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Experimental Section 
All reactions involving air sensitive reagents/intermediates were 
performed under an atmosphere of argon using standard Schlenk techniques. 
Reaction solvents were distilled from appropriate drying agents under argon. 
THF, ether and methyl tert-butyl ether were dried and distilled over 
sodium/benzophenone. Grignard reagents were purchased from Acros and 
Sigma-Aldrich. All organolithium and Grignard reagents were titrated using 
Gilman Double titration procedure before use. Saturated NH4Cl/NH3 
solution pH 8 was prepared by mixing 8 mL of 35% v/v NH3 in 500 mL 
saturated NH4Cl(aq). All other solvents and reagents were used as received 
from commercial suppliers. Column chromatography was performed using 
Davisil silicagel 60 and TLC analysis carried out on Merck silicagel 60 
F254nm. Nuclear magnetic resonance (NMR) spectra (
1H, 13C) were recorded 
on either Joel EX270 or Bruker AV400, DPX400, AV(III)400 or AV500 
spectrometers, using CDCl3 as the deuterated solvent. Chemical shift values 
are reported in ppm using solvent resonances as internal standards (CHCl3: 
δ 7.27 for 1H, δ 77.0 for 13C). Coupling constants (J) are quoted in Hertz. 
Carbon NMR multiplicities and connectivities were assigned using DEPT 
and HMQC experiments. Infrared spectra were recorded on either Nicolet 
Avatar 320 FTIR using Nicolet Avatar 360 FT-IR reflecting probe (ATR 
diffuse reflectance) or Perkin Elmer 1600 FTIR (thin films). High 
resolution mass spectra (HRMS) were recorded on a Bruker ApexIV FT-
ICRMS using electron-impact ionisation (EI) or Bruker MicroTOF LC-MS 
using electrospray ionisation (ESI). Mass spectra (MS) were recorded on 
MALDI-TOFMS using Bruker Ultraflex. Elemental analyses were 
performed using an Exeter Analytical CE-440 instrument. Melting points 
were determined using a Stuart Scientific SMP3 melting point apparatus 
and are uncorrected. X-ray data for: CCDC 931593 (rac-9f) are available 
from the Cambridge Crystallographic database 
(http://webcsd.ccdc.cam.ac.uk/) by quoting the appropriate CCDC number 
above. Compound 10 was prepared by a literature route.[11] 
 
Synthesis of 6-substituted fulvene 
1-(cyclopenta-2,4-dien-1-ylidenemethyl)-2-methoxybenzene (6): 
Prepared as described in the literature,[7] with minor modifications. 2-
Methoxybenzaldehyde (16.3 g, 0.12 mol) and excess freshly fractionated 
cyclopentadiene (38-41 oC, 25.2 mL, 0.30 mol) were dissolved in methanol 
(120 mL) to give a colourless solution which on dropwise addition of 
pyrrolidine (15.0 mL, 0.18 mol), the solution changed colour from 
colourless through yellow through dark red. The reaction was left to stir at 
room temperature whilst being monitored by TLC (pentane: CH2Cl2 4:1). 
After 60 min, acetic acid (18.0 mL, 0.32 mol) was added. The mixture was 
diluted with ether (300 mL) and deionized water (50.0 mL). After 
extraction from the aqueous layer (2 x 100 mL diethyl ether), the combined 
organic portions were washed twice with brine (2 x 80 mL) and once with 
deionized water (50 mL) and dried over anhydrous MgSO4. The volatiles 
were evaporated in vacuo. (CARE! 6 is highly malodorous). The crude 
product (21.1 g, 95%) obtained as a red oil, was used immediately to avoid 
Diels-Alder dimerization which was facile in the neat liquid (ca. 10% over 
7 days at -20 oC as detected by NMR spectroscopy). Alternatively, a 3.00 g 
portion of such contaminated product was filtered through a 40 mm pad of 
silica gel, eluting first with pentane (2 x 100 mL), and then with pentane: 
CH2Cl2 4:1 (2 x 100 mL). The last two pentane-dichloromethane fractions 
were combined and evaporated in vacuo yielding a light red oil (2.44 g, 
81%) which was stored at -20 oC. Rf  = 0.34 (pentane:CH2Cl2 4:1) 
1H NMR 
(400.1 MHz, CDCl3, 25 
oC): δ = 3.91 (s, 3H, -OCH3), 6.43 (dt, 1 H, J = 5.1, 
1.8 Hz, H-C(4)), 6.58 (ddd, 1H, J = 5.1, 1.6 Hz, 0.6 Hz, H-C(1)), 6.69-6.72 
(m, 2H, H-C(2) and H-C(3)), 6.95 (dd, 1H, J = 8.3, 0.6 Hz, H-C(3’)), 7.06 
(dddd, 1H, J = 7.6, 7.5, 1.0, 0.6 Hz, H-C(5’)), 7.39 (ddd, 1H, J = 7.3, 1.6, 
1.6 Hz, H-C(4’)), 7.62 (br, s, unresolved long range couplings, 1H, H-
C(6)), 7.66 (dd, 1H, J = 7.8 Hz & 1.8 Hz, H-C(6’)). 13C NMR (100.6 MHz, 
CDCl3, 25 
oC): δ = 55.5 (OCH3), 110.5 (C(3’)), 120.5 (C(5’)), 120.6 (C(2 or 
3)), 125.9 (C(1’)), 126.8 (C(4)), 130.5 (C(1 or 4’)), 130.6 (C(1 or 4’)), 
132.4 (C(6’)), 133.7 (C(6)), 134.7 (C(2 or 3)), 144.9 (C(5), 158.4 (C(2’)). 
This previously uncorrelated data was obtained using HMQC, HMBC and 
DEPT 90/135. IR (thin film):   = 3070, 3002, 2937, 2836, 1622, 1597, 
1489, 1464, 1339, 1302, 1249, 1109, 1049, 1027, 903, 842, 753, 624 cm-1. 
MS (EI+•) [M+1]+• (13.7%) m/z = 185.1, [M+•] (100%) m/z = 184.1, [M-H]+• 
(38.7%) 183.1, [M-CH3]
+• (77.6%) 169.1, [M-OCH3]
+• (44.9%) 153.1. 
HRMS (EI+•) (M+•) Calcd. for C13H12O: 184.0888 g mol
-1, found: 184.0881 
g mol-1.  
 
Synthesis of (±)-substituted cyclopentadienyl compounds 7 
General Procedure for CuBrSMe2 catalysed additions 6 
To a dry Schlenk tube, equipped with a magnetic stirrer and a septum, 
CuBrSMe2 (206 mg, 1.00 mmol, 10 mol-%) was added to dry THF (30.0 
mL) and left to stir at room temperature (15 min). The solution was cooled 
to -10 oC and the appropriate Grignard reagent (25.0 mmol, 2.5 equiv. - 
from a typically 0.50–0.90 M THF solutions, 20 wt% THF-toluene solution 
or 1.00–3.00 M ether solutions) was added dropwise and the reaction was 
left to stir (15 min) at -10 oC. A colour change from yellow to purple was 
noted. Neat (6) (1.84 g, 10.0 mmol, 1.0 equiv.) was dissolved in dry THF 
(10.0 mL) and added to the Grignard-cuprate solution dropwise. The 
reaction was then stirred for 16 h at -10 oC. Saturated NH4Cl/NH3 solution 
pH 8 (25 mL) was added dropwise to quench the reaction, which was then 
allowed to warm to room temperature with rapid stirring. The reaction 
mixture was diluted with ether (60 mL) and the organic phase extracted, 
washed with NH4Cl/NH3 solution pH 8 (15 mL) and brine (2 x 40 mL). The 
organic layer was then dried over MgSO4. All volatiles were removed 
under reduced pressure to yield the crude product, which was then purified 
by column chromatography (pentane-CH2Cl2) to yield the purified 
products. 
  
General Procedure for CuI/PPh3 catalysed additions to 6 
To a dry Schlenk tube, equipped with a magnetic stirrer and a septum, 
CuI (152 mg, 0.80 mmol, 8.0 mol-%) and triphenylphosphine (262 mg, 
1.00 mmol, 10 mol-%) were added to dry methyl tert-butyl ether (30 mL) 
and left to stir at room temperature (30 min). The solution was cooled 
to -10 oC and the appropriate Grignard reagent (25.0 mmol, 2.5 equiv. from 
a 2.80–3.00 M ether solution) was added dropwise and the reaction was left 
to stir (15 min) at -10 oC. Neat (6) (1.84 g, 10.0 mmol, 1.0 equiv.) was 
dissolved in dry methyl tert-butyl ether (10 mL) and added to the Grignard-
cuprate solution dropwise. The reaction was then stirred for 16 h at -10oC. 
Quenching and work-up was carried out as above for the CuBrSMe2 
promoted reactions. 
 
General procedure for CuCN/LiCl catalysed additions to 6  
To a dry Schlenk tube, equipped with a magnetic stirrer and a septum 
was added dried LiCl (63.6 mg, 1.50 mmol, 5.0 mol-%) and CuCN (134 
mg, 1.50 mmol, 5.0 mol-%) (TOXIC!). The mixture was then heated under 
vacuum (5 min) using a hot air gun (>100 oC), cooled to room temperature, 
flushed with argon and dry THF (50 mL) was added. The solution was 
cooled to -10 oC and a solution of 0.83 M ethylmagnesium bromide in THF 
(45.0 mL, 37.5 mmol, 2.5 equiv.) was added dropwise. A colour change 
from colourless to grey then purple. Other Grignard reagents resulted in 
equivalent solutions. Neat (6) (2.76 g, 15.0 mmol, 1.0 equiv.) was dissolved 
in 25. mL dry THF. The latter solution was added to the complexed 
Grignard solution dropwise. A colour change from dark purple to yellow 
was noted. The reaction was then stirred for 16 h at -10 oC. Saturated NH4C 
/NH3 solution pH 8 (35 mL) was then added dropwise to quench the 
reaction, which was then allowed to warm to room temperature with rapid 
stirring. The reaction mixture was diluted with ether (90 mL) and the 
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organic phase extracted, washed with NH4Cl/NH3 solution pH 8 (15 mL) 
and brine (2 x 50 mL). The organic layer was then dried over MgSO4. 
Aqueous cyanide residue were quenched with bleach. All volatiles were 
removed under reduced pressure to yield the crude product, which was then 
purified by column chromatography (pentane-CH2Cl2) to yield the purified 
product.  
 
1-(1-(Cyclopenta-1,3-dien-1-yl)propyl)-2-methoxybenzene and 1-(1-
(cyclopenta-1,4-dien-1-yl)propyl)-2-methoxy benzene (7a): Prepared by 
the CuBrSMe2 procedure using EtMgBr (8.7 mL of 2.90 M ether solution, 
25.0 mmol, 2.5 equiv.). The crude product was purified by flash column 
chromatography on silica gel (pentane-CH2Cl2 8:1, Rf  0.32) to yield 7a as a 
colourless oil (1.82 g, 85%). The individual / tautomer (0.8:1.2 ratio) 
signals could not be uniquely identified and are referred as tautomer 1 and 
tautomer 2 and integrated on this basis. 1H NMR (400.2 MHz, CDCl3, 25 
oC): δH  0.92 (t, 1.2 H, J = 7.3 Hz, CH2Me tautomer 1) overlapped by 0.93 
(t, 1.8 H, J = 7.3 Hz, CH2Me tautomer 2), 1.81-2.08 (m, 2 H, CH2Me both 
tautomers), 2.82-2.87 (br, 0.8 H, CH2 in Cp tautomer 1), 2.98-3.02 (br, 1.2 
H, CH2 in Cp tautomer 2), 3.85 (s, 1.2 H, OMe tautomer 1) overlapped by 
3.86 (s, 1.8 H, OMe tautomer 2), 4.12-4.22 (m, 1.0 H, CHEt both 
tautomers), 6.10-6.15 (m, 0.6 H, Cp tautomer 2), 6.23-6.31 (m, 0.8 H, Cp 
tautomer 1), 6.36-6.45 (m, 1.2 H, Cp  tautomer 2), 6.45-6.48 (m, 0.4 H, Cp  
tautomer 1), 6.87-6.96 (m, 2.0 H, Ar both tautomers), 7.11-7.23 (m, 2.0 H, 
Ar both tautomers). 13C NMR (100.6 MHz, CDCl3, 25 
oC): δC 12.5 (CH2Me 
both tautomers), 27.3 (MeCH2 tautomer 2), 27.8 (MeCH2 tautomer 1), 39.6 
(CHEt tautomer 2), 40.4 (CHEt tautomer 1), 41.0 (CH2 in Cp tautomer 2), 
42.6 (CH2 in Cp tautomer 1), 55.5 (OMe both tautomers), 110.6 (Ar both 
tautomers), 120.6 (Ar both tautomers), 125.8 (Cp tautomer 2), 126.3 (Cp 
tautomer 1), 126.8 (Ar tautomer 1), 126.9 (Ar tautomer 2), 127.9 (Ar 
tautomer 1), 128.0 (Ar tautomer 2), 130.7 (Cp tautomer 1), 132.1 (Cp 
tautomer 2), 132.9 (Cp tautomer 2), 133.1 (Cp tautomer 1), 133.6 (Cp 
tautomer 1), 134.6 (Cp tautomer 2), 149.9 (Cp-C-CHEt tautomer 2), 152.8 
(Cp-C-CHEt tautomer 1), 157.1 (C-O-Me tautomer 1), 157.3 (C-O-Me 
tautomer 2). IR (thin film):   = 3064, 2961, 2932, 2874, 2835, 1598, 1490, 
1463, 1241, 1031, 899, 752 cm-1. HRMS (EI+•) (M+•) Calcd. for C15H18O – 
214.1358, found: 214.1360. CHN Anal. calcd. for C15H18O: C, 84.07; H, 
8.47; found: C, 84.01; H, 8.67. Also prepared according to the CuCN/LiCl 
procedure to yield 2.82 g, 88%. 
 
1-(1-(Cyclopenta-1,3-dien-1-yl)pentyl)-2-methoxybenzene and 1-(1-
(cyclopenta-1,4-dien-1-yl)pentyl)-2-methoxybenzene (7b): Prepared by 
the CuBrSMe2 procedure using n-BuMgCl (14.6 g of 20 wt% THF/toluene 
solution, 25.0 mmol, 2.5 equiv.). The crude product was purified by flash 
column chromatography on silica gel (pentane:CH2Cl2 6:1, Rf  0.34) to 
yield 7b as a colourless oil (2.10 g, 87%). The individual / tautomer 
(0.8:1.2 ratio) signals could not be uniquely identified and are referred as 
tautomer 1 and tautomer 2 and integrated on this basis. 1H NMR (400.1 
MHz, CDCl3, 25 
oC): δH 0.88 (t, 3.0 H, J = 7.0 Hz, CH2Me both tautomers), 
1.17-1.39 (m, 4.0 H, C2H4Me both tautomers), 1.75-2.00 (m, 2.0 H, 
CH2C3H7 both tautomers), 2.80-2.85 (m, 0.8 H, CH2 in Cp tautomer 1), 
2.95-3.01 (m, 1.2 H, CH2 in Cp tautomer 2), 3.84 (s, 1.2 H, OMe tautomer 
1) overlapped by 3.84 (s, 1.8 H, OMe tautomer 2), 4.18-4.27 (m, 1.0 H, 
CH-Bu both tautomers), 6.06-6.12 (m, 0.6 H, Cp tautomer 2), 6.21-6.27 (m, 
0.8 H, Cp tautomer 1), 6.36-6.47 (m, 1.6 H, Cp both tautomers), 6.85-6.94 
(m, 2.0 H, Ar both tautomers), 7.10-7.20 (m, 2.0 H, Ar both tautomers). 13C 
NMR (100.6 MHz, CDCl3, 25 
oC): δC 14.0 (CH2Me both tautomers), 22.7 
(C2H4Me both tautomers), 30.0 (C2H4Me tautomer 2) overlapped by 30.1 
(C2H4Me tautomer 1), 34.1 (CH2C3H7 tautomer 2), 34.6 (CH2C3H7 tautomer 
1), 37.7 (CH-Bu tautomer 2), 38.5 (CH-Bu tautomer 1), 41.0 (CH2 in Cp 
tautomer 2), 42.6 (CH2 in Cp tautomer 1), 55.5 (OMe both tautomers), 
110.6 (Ar both tautomers), 120.6 (Ar both tautomers) 125.7 (Cp tautomer 
2), 126.2 (Cp tautomer 1), 126.7 (Ar both tautomers), 127.9 (Ar tautomer 
1), 128.0 (Ar tautomer 2), 130.7 (Cp tautomer 2), 132.1 (Cp tautomer 1), 
133.1 (Cp tautomer 2), 133.2 (Cp tautomer 2), 133.9 (tautomer 1), 134.6 
(Cp tautomer 2), 150.1 (Cp-C-CH tautomer 2), 153.0 (Cp-C-CH tautomer 
1), 157.0 (C-O-Me tautomer 1, 157.1 (C-O-Me tautomer 2). IR (thin film): 
  = 3064, 3028, 2998, 2931, 2859, 1598, 1491, 1463, 1439, 1367, 1288, 
1242, 1117, 1052, 1032, 931, 899, 752, 676 cm-1. HRMS (EI+•) (M+•)  
Calcd. for C17H22O – 242.1671, found 242.1670. CHN Anal. calcd. for 
C17H22O: C, 84.25; H, 9.15; found: C, 84.27; H, 9.10. 
 
1-(1-(cyclopenta-1,3-dien-1-yl)-3-methylbutyl)-2-methoxybenzene and 
1-(1-(cyclopenta-1,4-dien-1-yl)-3-methylbutyl)-2-methoxybenzene (7c): 
Prepared by the CuBrSMe2 procedure using using iBuMgCl (12.5 mL of 
2.00 M ether solution, 25.0 mmol, 2.5 equiv.). The crude product was 
purified by flash column chromatography on silica gel (gradient 
pentane/CH2Cl2 initially 6:1, Rf 0.38) to yield 7d as a colourless oil (2.23 g, 
92%). The individual / tautomer (0.8 : 1.2 ratio) signals could not be 
uniquely identified and are referred as tautomer 1 and tautomer 2 and 
integrated on this basis. 1H NMR (400.1 MHz, CDCl3, 25 
oC): δH 0.89-0.93 
(m, 6 H, CH3CHCH3 both tautomers), 1.4-1.53 (m, 1.0 H, CH3CHCH3 both 
tautomers), 1.68-1.83 (m, 2.0 H, CHCH2C3H7 both tautomers), 2.80-2.85 
(m, 0.8 H, CH2 in Cp tautomer 1), 2.95-2.99 (m, 1.2 H, CH2 in Cp tautomer 
2), 3.83 (s, 1.2 H, OMe tautomer 1) overlapped by 3.84 (s, 1.8 H, OMe 
tautomer 2), 4.30-4.40 (m, 1.0 H, CH-iBu both tautomers), 6.05-6.10 (m, 
0.6 H, Cp tautomer 2), 6.20-6.28 (m, 0.8 H, Cp tautomer 1), 6.33-6.47 (m, 
1.5 H, Cp both tautomers), 6.85-6.93 (m, 2.0 H, Ar both tautomers), 7.09-
7.19 (m, 2.0 H, Ar both tautomers). 13C NMR (100.6 MHz, CDCl3, 25 
oC): 
δC 22.4 (CH3CHCH3 tautomer 1), 22.5 (CH3CHCH3 tautomer 2), 23.0 
(CH3CHCH3 tautomer 2), 23.1 (CH3CHCH3 tautomer 1), 25.8 (CH3CHCH3 
both tautomers), 35.5 (CH-iBu tautomer 2), 36.3 (CH-iBu tautomer 1), 41.0 
(CH2 in Cp tautomer 2), 42.6 (CH2 in Cp tautomer 1), 43.8 (CHCH2C3H7 
tautomer 2), 44.2 (CHCH2C3H7 tautomer 1), 55.5 (OMe both tautomers), 
110.6 (Ar tautomer 2) overlapped by 110.7 (Ar tautomer 1), 120.6 (Ar both 
tautomers) 125.6 (Cp tautomer 2), 126.1 (Cp tautomer 1), 126.7 (Ar 
tautomer 1), 126.8 (Ar tautomer 2), 128.0 (Ar tautomer 1), 128.2 (Ar 
tautomer 2), 130.7 (Cp tautomer 2), 132.1  (Cp tautomer 1), 133.2 (Cp both 
tautomers), 133.8 (Cp tautomer 1), 134.7 (Cp tautomer 2), 150.3 (Cp-C-CH 
tautomer 2), 153.2 (Cp-C-CH tautomer 1), 157.0 (C-O-Me tautomer 1, 
157.1 (C-O-Me tautomer 2). IR (thin film):   = 3064, 2954, 2868, 2835, 
1598, 1491, 1464, 1438, 1366, 1288, 1241, 1168, 1096, 1053, 1032, 899, 
807, 752, 677, 622 cm-1. HRMS (EI+•) (M+•) Calcd. for C17H22O – 
242.1671, found 242.1676. CHN Anal. calcd. for C17H22O: C, 84.25; H, 
9.15; found: C, 83.85; H, 9.12. 
 
1-(1-(Cyclopenta-1,3-dien-1-yl)but-3-en-1-yl)-2-methoxybenzene and 1-
(1-(cyclopenta-1,4-dien-1-yl)but-3-en-1-yl)-2-methoxybenzene (7d): 
Prepared by the CuBrSMe2 procedure using using allylmagnesium 
bromide in (25.0 mL of 1.00 M ether solution, 25.0 mmol, 2.5 equiv.). The 
crude product was purified by flash column chromatography on silica gel 
(gradient pentane/CH2Cl2 initially 6:1, Rf 0.28) to yield 7c as a colourless 
oil (2.06 g, 91%). The individual / tautomer (0.9:1.1 ratio) signals could 
not be uniquely identified and are referred as tautomer 1 and tautomer 2 and 
integrated on this basis. 1H NMR (400.1 MHz, CDCl3, 25 
oC): δH 2.55-2.77 
(m, 2.0 H, CH2CH-Cp both tautomers), 2.82-2.86 (m, 0.9 H, CH2 in Cp 
tautomer 1), 2.96-3.02 (m, 1.1 H, CH2 in Cp tautomer 2), 3.83 (s, 1.3 H, 
OMe tautomer 1), 3.84 (s, 1.7 H, OMe tautomer 2), 4.26-4.37 (m, 1.0 H, 
CH2CH-Cp both tautomers), 4.90-4.95 (m, 1.0H, CH2C2H3-CH-Cp both 
tautomers), 4.98-5.05 (m, 1.0 H, CH2C2H3-CH-Cp both tautomers), 5.72-
5.85 (m, 1.0 H, CHCH2CH-Cp both tautomers), 6.12-6.15 (m, 0.5 H, Cp 
tautomer 2), 6.22-6.30 (m, 0.9 H, Cp tautomer 1), 6.36-6.42 (m, 1.1 H, Cp 
tautomer 2), 6.42-6.45 (m, 0.4 H, Cp tautomer 1), 6.85-6.93 (m, 2.0 H, Ar 
both tautomers), 7.08-7.20 (m, 2.0 H, Ar both tautomers). 13C NMR (100.6 
MHz, CDCl3, 25 
oC): δC 38.0 (CH-allyl tautomer 1), 38.5 (CH-allyl 
tautomer 2), 38.8 (CH2CH-Cp tautomer 2), 39.0 (CH2CH-Cp tautomer 1), 
41.0 (CH2 in Cp tautomer 2), 42.7 (CH2 in Cp tautomer 1), 55.5 (OMe both 
tautomers), 110.6 (Ar both tautomers), 115.4 (CH2C2H3-CH-Cp tautomer 2) 
overlapped by 115.5 (CH2C2H3-CH-Cp tautomer 1), 120.5 (Ar tautomer 2) 
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overlapped by 120.6 (Ar tautomer 1) 126.3 (Cp tautomer 2), 126.8 (Cp 
tautomer 1), 127.0 (Ar both tautomers), 128.1 (Ar tautomer 1), 128.3 (Ar 
tautomer 2), 131.0 (Cp tautomer 2), 132.1 (Cp tautomer 1), 132.3 (Cp 
tautomer 2), 133.1 (Cp tautomer 1), 133.3 (Cp tautomer 2), 134.6 (Cp 
tautomer 1), 137.5 (CHCH2CH-Cp both tautomers), 149.2 (Cp-C-CH 
tautomer 2), 151.9 (Cp-C-CH tautomer 1), 156.9 (C-O-Me tautomer 1), 
157.0 (C-O-Me tautomer 2). IR (thin film):   = 3072, 3029, 3001, 2935, 
2836, 1640, 1599, 1586, 1491, 1463, 1439, 1365, 1339, 1289, 1242, 1186, 
1162, 1114, 1052, 1032, 995, 951, 911, 899, 808, 753, 678, 619, 572, 503, 
478, 460 cm-1. HRMS (EI+•) (M+•) Calcd. for C16H18O – 226.1358, found 
226.1360. CHN Anal. calcd. for C16H18O: C, 84.91; H, 8.02; found: C, 
84.90; H, 8.02. 
 
1-(1-(cyclopenta-1,3-dien-1-yl)ethyl)-2-methoxybenzene and 1-(1-
(cyclopenta-1,4-dien-1-yl)ethyl)-2-methoxybenzene (7e): Prepared by the 
CuI/PPh3 procedure using MeMgBr (8.3 mL of 3.00 M ether solution, 25.0 
mmol, 2.5 equiv.). The crude product was purified by flash column 
chromatography on silica gel (gradient pentane/CH2Cl2 initially 10:1, Rf 
0.30) to yield 7e as a colourless oil (1.83 g, 91%). The individual / 
tautomer (1.2:0.8 ratio) signals could not be uniquely identified and are 
referred as tautomer 1 and tautomer 2 and integrated on this basis. 1H NMR 
(400.2 MHz, CDCl3, 2 5
oC): δH 1.46 (d, 3.0 H, J = 7.2 Hz, CHMe both 
tautomers), 2.81-2.86 (m, 1.2 H, CH2 in Cp tautomer 1), 2.99-3.02 (m, 0.8 
H, CH2  in Cp tautomer 2), 3.85 (s, 1.8 H, OMe tautomer 1) overlapped by 
3.86 (s, 1.2 H, OMe tautomer 2), 4.25-4.40 (m, 1.0 H, CHMe both 
tautomers), 6.08-6.13 (m, 0.4 H, Cp tautomer 2), 6.22-6.29 (m, 1.2 H, Cp 
tautomer 1), 6.33-6.41 (m, 0.8 H, Cp tautomer 2), 6.42-6.48 (m, 0.6 H, Cp 
tautomer 1), 6.85-6.93 (m, 2.0 H, Ar both tautomers), 7.03-7.08 (m, 1.0H, 
Ar both tautomers), 7.14-7.21 (m, 1.0 H, Ar both tautomers). 13C NMR 
(100.6 MHz, CDCl3, 25 
oC): δC 19.9 (MeCH tautomer 2), 20.4 (MeCH 
tautomer 1), 32.4 (MeCH tautomer 2), 33.1 (MeCH tautomer 1), 41.0 (CH2 
in Cp tautomer 2), 42.7 (CH2 in Cp tautomer 1), 55.5 (OMe both 
tautomers), 110.5 (Ar both tautomers), 120.6 (Ar both tautomers), 125.5 
(Cp tautomer 2), 126.2 (Cp tautomer 1), 126.8 (Ar tautomer 1), 126.9 (Ar 
tautomer 2), 127.7 (Ar tautomer 1), 127.9 (Ar tautomer 2), 131.0 (Cp 
tautomer 1), 132.1 (Cp tautomer 1), 133.3 (Cp tautomer 2), 134.2 (Cp 
tautomer 2), 134.7 (Cp tautomer 2), 135.2 (Cp tautomer 1), 151.1 (Cp-C-
CH tautomer 2), 153.9 (Cp-C-CHEt tautomer 1), 156.5 (C-O-Me tautomer 
1), 156.8 (C-O-Me tautomer 2). IR (thin film):   = 3061, 2962, 2835, 1599, 
1491, 1463, 1438, 1367, 1289, 1241. 1163, 1111, 1030, 931, 899, 808, 753, 
677, 573, 503 cm-1. HRMS (EI+•) (M+•) Calcd. for C14H16O – 200.1201, 
found: 200.1205.  
 
1-(Cyclopenta-1,3-dien-1-yl(phenyl)methyl)-2-methoxybenzene and 1-
(cyclopenta-1,4-dien-1-yl(phenyl)methyl)-2-methoxybenzene (7f): 
Prepared by the CuI/PPh3 procedure using PhMgBr (9.0 mL of 2.80 M 
ether solution, 25.0 mmol, 2.5 equiv.). The crude product was purified by 
flash column chromatography on silica gel (gradient pentane/CH2Cl2 
initially 10:1, Rf  0.20) to yield 7f as a colourless oil (1.73 g, 66%). The 
individual / tautomer (0.9:1.1 ratio) signals could not be uniquely 
identified and are referred as tautomer 1 and tautomer 2 and integrated on 
this basis. 1H NMR (400.2 MHz, CDCl3, 25 
oC): δH: 2.99-3.04 (br, 0.9 H, 
CH2 in Cp tautomer 1), 3.05-3.09 (br, 1.1 H, CH2 in Cp tautomer 2), 3.81 (s, 
3.0 H, OMe both tautomers), 5.63-5.67 (br, 0.5 H, CHPh tautomer 2), 5.67-
5.71 (br, 0.5 H, CHPh tautomer 1), 5.81-5.84 (m, 0.5 H, Cp), 5.98-6.02 (br, 
m, 0.5 H, Cp), 6.37-6.41 (m, 0.5 H, Cp), 6.43-6.47 (m, 0.5 H, Cp), 6.47-
6.52 (m, 1.0 H, Cp), 6.91-6.99 (m, 2.0 H, Ar both tautomers), 7.07-7.14 (m, 
1.0 H, Ar both tautomers), 7.22-7.30 (m, 4.0 H, Ar & Ph both tautomers), 
7.31-7.37 (m, 2.0 H, Ph both tautomers). 13C NMR (100.6 MHz, CDCl3, 25 
oC): δC 41.0 (CH2 in Cp tautomer 2), 43.6 (CH2 in Cp tautomer 1), 44.7 
(CHPh tautomer 2), 45.4 (CHPh tautomer 1), 55.6 (OMe both tautomers), 
110.6 (Ar tautomer 1), 110.7 (Ar tautomer 2), 120.3 (Ar both tautomers), 
125.9 (Ph both tautomers), 127.3 (Ar tautomer 1), 127.4 (Ar tautomer 2), 
128.0 (Ph x 2 both tautomers), 128.9 (Ph x 2 tautomer 1), 129.0 (Ph x 2 
tautomer 2), 129.1 (Ar tautomer 2), 129.6 (Ar tautomer 1), 129.7 (Cp 
tautomer 2), 130.0 (Cp tautomer 1), 131.6 (Cp tautomer 2), 131.8 (Cp 
tautomer 2), 132.0 (Cp tautomer 2), 132.6 (Cp tautomer 1), 133.4 (Cp 
tautomer 1), 135.1 (Cp tautomer 2), 143.4 (Ph-C-CH tautomer 2), 143.9 
(Ph-C-CH tautomer 1), 149.1 (Cp-C-CH tautomer 2), 151.6 (Cp-C-CH 
tautomer 1), 156.8 (C-O-Me tautomer 1), 157.0 (C-O-Me tautomer 2). IR 
(thin film):   = 3061, 3026, 2935, 2835, 1598, 1450, 1462, 1438, 1361, 
1289, 1243, 1162, 1105, 1051, 1030, 900, 755, 700, 634 cm-1. HRMS (EI+•) 
(M+•) Calcd. for C19H18O – 262.1358, found: 262.1361. 
 
General Procedure for synthesis of rac/meso-substituted titanocenes 9 
A flame dried Schlenk tube was left to cool under vacuum for 30 min 
and then weighed under vacuum. Under a stream of argon atmosphere, 7 
(1.0 equiv.) was added, followed by dry ether or methyl tert-butyl ether 
(4.00 mL per 1.00 mmol of 7). The mixture was cooled to 0 oC, followed by 
the addition of n-BuLi 1.60 M in hexane (1.1 equiv.). The solution was left 
to stir for 30 min at 0 oC yielding a white precipitate of the lithium 
substituted-cyclopentadienide 8 in a faint yellow solution. The solvent was 
removed from 8 by cannula filtration procedure, and the solid washed twice 
with dry ether (2 x 1.0 mL per 1.0 mmol of 7) and re-filtered under argon. 
The precipitate was dried under vacuum at 0.1 mmHg for 1 h and weighed 
under vacuum. The lithium substituted-cyclopentadienide 8 (2.0 equiv.) 
was dissolved in dry THF (4.0 mL per 1.0 mmol of 8) to give a colourless 
solution. In another Schlenk tube, titanium tetrachloride 1.00 M solution in 
toluene (1.0 equiv.) was dissolved in dry THF (8.0 mL per 1.0 mmol of 
titanium tetrachloride) to give a yellow solution. The solution of titanium 
tetrachloride was added to the solution of 8 via cannula at room 
temperature, to give a dark red solution and refluxed for 16 h at 85 oC. The 
resultant solution was then cooled and the solvent was removed under 
reduced pressure. The remaining brown residue was extracted with 
chloroform and filtered through Celite to remove LiCl. The solvent 
removed in vacuo yielding the crude solid material. Purification was carried 
out by direct infusion of pentane on top of a saturated solution of 9 in 
CH2Cl2 ( final mixture ca. 5:1 pentane: CH2Cl2). 
 
Rac/meso-dichloridobis(1-propyl-1’-(2-methoxyphenyl)-5-
cyclopentadienyl)titanium (9a): Prepared using 7a (535 mg, 2.50 mmol, 
1.0 equiv.), dry ether (10 mL) and n-BuLi (1.7 mL, 2.75 mmol, 1.1 equiv.) 
yielding lithium substituted-cyclopentadienide 8a (410 mg, 1.86 mmol, 
74%). This intermediate (1.86 mmol, 2.0 equiv.) was dissolved in 7.5 mL 
dry THF to give a colourless solution. Titanium tetrachloride (0.93 mmol, 
0.93 mL, 1.0 equiv.) was dissolved in 7.5 mL dry THF to give a yellow 
solution. After purification, a red solid was obtained (359 mg, 71% - based 
on titanium). The individual rac and meso diastereomers (1:1 ratio) signals 
could not be uniquely identified and are thus identified as isomer 1 or 2. 
M.p. 173-174 oC. 1H NMR (500.1 MHz, CDCl3, 22 
oC): δH 0.76 (t, 3 H, J = 
7.5 Hz, CH2Me isomer 1 or 2) overlapped by 0.76 (t, 3 H, J = 7.5 Hz, 
CH2Me isomer 1 or 2), 1.88-2.03 (br, 2 H, CH2Me both isomers), 2.08-2.23 
(m, 2 H, CH2Me both isomers), 3.78 (s, 6 H, 2 x OMe, both isomers), 4.42 
(br, 2 H, CHEt both isomers), 5.97 (AB, 1 H, JAB = 2.0 Hz, Cp isomer 1), 
6.01 (AB, 1 H, JAB = 2.0 Hz, Cp isomer 2), 6.06 (AB, 1 H, JAB = 2.5 Hz, Cp 
isomer 1), 6.17 (AB, 1 H, JAB = 2.5 Hz, Cp isomer 2), 6.40 (AB, 1 H, JAB = 
2.5 Hz, Cp isomer 2), 6.46 (AB, 1 H, JAB = 2.5 Hz, Cp isomer 1), 6.71 (AB, 
1 H, JAB = 2.5 Hz, Cp isomer 2), 6.73 (AB, 1 H, JAB = 2.5 Hz, Cp isomer 1), 
6.86-6.92 (m, 4 H, H-C(4) and H-C(6) Ar, both isomers), 7.03 (br d, 2H, J 
= 6.9 Hz, H-C(3) Ar, both isomers), 7.20 (ddd, 1 H, J = 7.5, 7.0, 1.0 Hz, H-
C(5) Ar) overlapped by 7.25 (ddd, 1 H, J = 7.5, 7.0, 1.0 Hz, H-C(5) Ar) 13C 
NMR (125.8 MHz, CDCl3, 25 
oC): δC 11.9 (CH2Me both isomers), 26.2 
(CH2Me isomer 1 or 2), 26.3 (CH2Me isomer 1 or 2), 42.1 (CHEt both 
isomers), 55.4 (OMe both isomers), 111.1 (C(6) Ar both isomers), 115.4 
(br, Cp isomer 1), 116.4 (br, Cp isomer 2), 117.4 (Cp isomer 2), 118.3 (Cp 
isomer 1), 118.8 (Cp isomer 1), 119.2 (Cp isomer 2), 120.7 (C(3) or C(4) 
Ar both isomers), 120.7 (C(3) or C(4) both isomers Ar), 121.9 (Cp isomer 
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2), 123.1 (Cp isomer 1), 127.6 (C(5) Ar both isomers), 129.9 (br, ipso-Cp 
isomer), 131.7 (br, ipso-Cp isomer), 142.2 (C(2) Ar isomer 1 or 2), 142.5 
(C(2) Ar isomer 1 or 2), 157.6 (C(1) Ar both isomers). IR (ATR.):   = 
3118, 2962, 2933, 2875, 2835, 1597, 1583, 1490, 1459, 1434, 1379, 1334, 
1290, 1242, 1183, 1157, 1117, 1080, 1048, 1025, 908, 838, 829, 797 775, 
752, 740, 712 cm-1. HRMS (ESI+) (M+Na+) Calcd. for C30H34Cl2NaO2Ti
+ – 
567.1308, found: 567.1319. CHN Anal. calcd. for C30H34Cl2O2Ti: C, 66.07; 
H, 6.28; found: C, 65.94; H, 6.28. 
 
Rac/meso-dichloridobis(1-pentyl-1’-(2-methoxyphenyl)-5-
cyclopentadienyl)titanium (9b): Prepared using 7b (606 mg, 2.50 mmol, 
1.0 equiv.), dry methyl tert-butyl ether (10 mL) and n-BuLi (1.7 mL, 2.75 
mmol, 1.1 equiv.) yielding 8b (170 mg, 27% yield). This intermediate (0.69 
mmol, 2.0 equiv.) dissolved in 2.8 mL dry THF to give a colourless 
solution. Titanium tetrachloride (0.34 mmol, 0.34 mL, 1.0 equiv.) was 
dissolved in 2.8 mL dry THF to give a yellow solution. After purification, a 
red solid was obtained (143 mg, 69% - based on titanium). The individual 
rac and meso diastereomers (1:1 ratio) signals could not be uniquely 
identified and are thus identified as isomer 1 or 2. M.p. 121-123 oC. 1H 
NMR (500.1 MHz, CDCl3, 22 
oC): δH 0.82 (t, 6 H, J = 7.5 Hz, CH2Me both 
isomers) 0.95-1.08 (br, 2 H, C2H4Me both isomers), 1.10-1.40 (m, 6 H, 
C2H4Me both isomers), 1.85-2.16 (m, 2.0 H, CH2C3H7 both isomers), 3.78 
(s, 6 H, 2 x OMe, both isomers), 4.49 (br, 2 H, CH-Bu both isomers), 5.95 
(s, 1 H, Cp isomer 1), 6.01 (s, 2 H, Cp both isomers), 6.16 (s, 1 H, Cp 
isomer 2), 6.39 (s, 1 H, Cp isomer 2), 6.48 (s, 1 H, Cp isomer 1), 6.69 (s, 1 
H, Cp isomer 2), 6.74 (s, 1 H, Cp isomer 1), 6.82-6.95 (m, 4 H, H-C(4) and 
H-C(6) Ar, both isomers), 7.03 (br d, 2 H, J = 6.0 Hz, H-C(3) Ar, both 
isomers), 7.20 (br t, 2 H, J = 7.5 Hz, H-C(5) Ar both isomers) 13C NMR 
(125.8 MHz, CDCl3, 25 
oC): δC 14.1 (CH2Me both isomers) 22.6 (CH2Me 
both isomers), 29.4 (CH2CH2Me both isomers), 33.0 (CHCH2C3H7 isomer 1 
or 2) overlapped by 33.1 (CHCH2C3H7 isomer 1 or 2), ≈39.5-40.5 (CHBu 
both isomers), 55.5 (OMe both isomers), 111.1 (C(6) Ar both isomers), 
115.2 (br, Cp isomer 1 or 2), 116.8 (br, Cp isomer 2), 117.6 (Cp isomer 2), 
118.1 (Cp isomer 1), 119.2 (Cp isomer 1 or 2), 119.6 (Cp isomer 1), 120.7 
(C(3) or C(4) Ar isomer 1 or 2) overlapped by 120.8 (C(3) or C(4) Ar 
isomer 1 or 2), 121.3 (Cp isomer 2), 123.0 (Cp isomer 1), 127.6 (C(5) Ar 
both isomers), 129.9 (br, ipso-Cp isomer), 132.2 (br, ipso-Cp isomer), 
142.3 (C(2) Ar isomer 1 or 2), 142.8 (C(2) Ar isomer 1 or 2), 157.5 (C(1) 
Ar both isomers). IR (ATR):   = 3105, 2954, 2928, 2869, 1596, 1585, 
1491, 1463, 1438, 1336, 1288, 1240, 1189, 1162, 1124, 1088, 1051, 1029, 
949, 843, 826, 804, 782, 753, 735, 714, 702, 685, 675 cm-1. MS (MALDI 
TOF – DCTB matrix, 10% laser): m/z 565.3 (M-Cl, 100%), 530.3 (M-2Cl, 
3%). CHN Anal. calcd. for C34H42Cl2O2Ti: C, 67.89; H, 7.04; found: C, 
67.80; H, 7.08. 
 
Rac/meso)-dichloridobis(1-(3-methylbutyl)-1’-(2-methoxyphenyl)-5-
cyclopentadienyl)titanium (9c): Prepared using 7c (735 mg, 3.00 mmol, 
1.0 equiv.), dry ether (12.1 mL) and n-BuLi (2.1 mL, 3.34 mmol, 1.1 
equiv.) yielding 8d (706 mg, 2.84 mmol, 94% yield). This intermediate 
(2.84 mmol, 2.0 equiv.) was dissolved in 11.5 mL dry THF to give a 
colourless solution. Titanium tetrachloride (1.42 mmol, 1.42 mL, 1.0 
equiv.) was dissolved in 11.5 mL dry THF to give a yellow solution. After 
purification, a red solid was obtained (682 mg, 80% - based on titanium). 
The individual rac and meso diastereomers (1:1 ratio) signals could not be 
uniquely identified and are thus identified as isomer 1 or 2. M.p. 161-162 
oC. 1H NMR (500.1 MHz, CDCl3, 50 
oC): δH 0.84 (d, 6 H, J = 6.4 Hz, 
CH3CHCH3 both isomers), 0.93 (d, 6 H, J = 6.8 Hz, CH3CHCH3 both 
isomers), 1.4-1.53 (m, 2 H, CH3CHCH3 both isomers), 1.75-2.15 (m, 4 H, 
CH2CHCp both isomers), 3.79 (s, 6 H, 2 x OMe, both isomers), 4.45-4.85 
(br, 2 H, CH-iBu both isomers), 5.94 (s, 1 H, Cp isomer 1), 6.00 (s, 2 H, Cp 
both isomers), 6.16 (s, 1 H, Cp isomer 2), 6.37 (s, 1 H, Cp isomer 2), 6.48 
(s, 1 H, Cp isomer 1), 6.65 (s, 1 H, Cp isomer 2), 6.72 (s, 1 H, Cp isomer 
1), 6.85-6.95 (m, 4 H, H-C(4) and H-C(6) Ar, both isomers), 7.00-7.15 (br, 
2 H, H-C(3) Ar, both isomers), 7.20 (t, 2 H, J = 7.6 Hz, H-C(5) Ar both 
isomers) 13C NMR (125.8 MHz, CDCl3, 25 
oC): δC 21.8 (CH3CHCH3 both 
isomers), 24.1 (CH3CHCH3 both isomers), 25.7 (CH3CHCH3 both isomers), 
42.8 (CH2CHCp both isomers), 55.5 (OMe both isomers), 111.3 (C(6) Ar 
both isomers), 117.5 (br, Cp isomer 1 or 2), 117.9 (br, Cp isomer 2), 119.2 
(Cp isomer 2), 119.8 (Cp isomer 1), 120.7 (C(3) or C(4) Ar isomer 1 or 2), 
120.9 (Cp both isomers), 122.7 (Cp isomer 1), 127.6 (C(5) Ar both 
isomers), 129.9 (br, ipso-Cp isomer 1 or 2), 132.4 (br, ipso-Cp isomer 1 or 
2), 142.6 (C(2) Ar isomer 1 or 2), 143.0 (C(2) Ar isomer 1 or 2), 157.6 
(C(1) Ar both isomers). IR (ATR):   = 3105, 2953, 2868, 2838, 1653, 1596, 
1586, 1491, 1464, 1438, 1384, 1364, 1327, 1287, 1242, 1187, 1168, 1119, 
1097, 1051, 1043, 1028, 906, 848, 828, 806, 754, 717, 702 cm-1. MS 
(MALDI TOF – DCTB matrix, 10% laser): m/z 565.3 (M-Cl, 100%), 530.3 
(M-2Cl, 11%). CHN Anal. calcd. for C34H42Cl2O2Ti: C, 67.89; H, 7.04; 
found: C, 67.73; H, 7.10. 
 
Rac/meso-dichloridobis(1-but-3-en-1-yl-1’-(2-methoxyphenyl)-5-
cyclopentadienyl)titanium (9d): Prepared using 7d (1.09 g, 4.8 mmol, 1.0 
equiv.), dry methyl tert-butyl ether (19.2 mL) and n-BuLi (3.3 mL, 5.28 
mmol, 1.1 equiv.) yielding 8c (785 mg, 71% yield). This intermediate (3.38 
mmol, 2.0 equiv) was dissolved in 13.5 mL dry THF to give a colourless 
solution. Titanium tetrachloride (1.70 mmol, 1.70 mL, 1.0 equiv.) was 
dissolved in 13.5 mL dry THF to give a yellow solution. After purification, 
a brown solid was obtained (713 mg, 74% - based on titanium). The 
individual rac and meso diastereomers (1:1 ratio) signals could not be 
uniquely identified and are thus identified as isomer 1 or 2. M.p. 139-140 
oC. 1H NMR (500.1 MHz, CDCl3, 25 
oC): δH  2.71-2.83 (m, 2 H, CH2CH-
Cp isomer 1 or 2), 2.87-2.97 (m, 2 H, CH2CH-Cp isomer 1 or 2), 3.78 (s, 6 
H, 2 x OMe both isomers), 4.55-4.70 (m, 2 H, CH2CH-Cp both isomers), 
4.80-4.85 (br s, 1 H, CH2C2H3-CH isomer 1 or 2), 4 (br s, 1 H, CH2C2H3-
CH isomer 1 or 2), 4.92-4.95 (br m, 1 H, CH2C2H3-CH isomer 1 or 2), 4.95-
4.97 (br m, 1 H, CH2C2H3-CH isomer 1 or 2), 5.58-5.67 (m, 2 H, 
CH2CHCH2 both isomers), 5.98 (AB, 1 H, JAq = 2.0 Hz, Cp isomer 1), 6.02 
(AB, 1 H, JAB = 2.5 Hz, Cp isomer 2), 6.08 (AB, 1 H, JAB = 2.0 Hz, Cp 
isomer 1), 6.18 (AB, 1 H, JAB = 2.0 Hz, Cp isomer 2), 6.41 (AB, 1 H, JAB = 
2.5 Hz, Cp isomer 2), 6.45 (AB, 1 H, JAB = 2.5 Hz, Cp isomer 1), 6.71-6.73 
(2 x AB, 2 H, JAB = 2.5 Hz, C5H4 both isomers), 6.85-6.91 (m, 4 H, H-C(4) 
and H-C(6) Ar, both isomers), 6.99-7.05 (t, 2 H, J = 6.5 Hz, H-C(3) Ar, 
both isomers), 7.20 (ddd, 2 H, J = 8.0, 7.5, 1.5 Hz, H-C(5) Ar). 13C NMR 
(125.8 MHz, CDCl3, 25 
oC): δC 37.5 (CH2CH-Cp isomer 1 or 2) overlapped 
by 37.5 (CH2CH-Cp isomer 1 or 2), 40.6 (Cp-CH-Ph both isomers), 55.4 
(OMe both isomers), 111.0 (C(6) Ar both isomers), 115.2 (br, Cp isomer 1), 
116.1 (CH2C2H3-CH both isomers) overlapped by 116.1 (Cp isomer 2), 
117.4 (Cp isomer 2), 118.4 (Cp isomer 1), 118.6 (Cp isomer 1), 119.3 (Cp 
isomer 2), 120.6 (C(3) or C(4) Ar both isomers), 121.8 (Cp isomer 2), 122.8 
(Cp isomer 1), 127.8 (C(5) Ar both isomers), 130.1 (br, ipso-Cp isomer), 
131.3 (br, ipso-Cp isomer), 136.4 (CH2CHCH2 both isomers), 141.5 (C(2) 
Ar isomer 1 or 2), 141.7 (C(2) Ar isomer 1 or 2), 157.2 (C(1) Ar both 
isomers). IR (ATR):   = 3074, 2939, 2836, 1639, 1598, 1588, 1492, 1462, 
1438, 1421, 1337, 1288, 1275, 1244, 1177, 1123, 1093, 1078, 1052, 1030, 
995, 960, 907, 847, 816, 786, 753, 732, 718 cm-1. MS (MALDI TOF – 
DCTB matrix, 10% laser): m/z 533.2 (M-Cl, 100%), 430.3 (M-2Cl, 6%). 
HRMS (ESI+) (M+Na+) Calcd. for C32H34Cl2O2TiNa
+ – 591.1308, found: 
591.1313. CHN Anal. calcd. for C32H34Cl2O2Ti: C, 67.50; H, 6.02; found: 
C, 67.86; H, 6.02. 
 
Rac/meso)-dichloridobis(1-ethyl-1’-(2-methoxyphenyl)-5-
cyclopentadienyl)titanium (9e): Prepared using 7e (802 mg, 4.00 mmol, 
1.0 equiv.), dry ether (16.0 mL) and n-BuLi (2.70 mL, 4.40 mmol, 1.1 
equiv.) yielding 8e (738 mg, 89%). This intermediate (3.58 mmoles, 2.0 
equiv.) was dissolved in 14.0 mL dry THF to give a colourless solution. 
Titanium tetrachloride (1.80 mmol, 1.80 mL, 1.0 equiv.) was dissolved in 
14.0 mL dry THF to give a yellow solution. After purification, a red solid 
was obtained with a yield (based on titanium) of 51% (472 mg, 0.91 mmol). 
The individual rac and meso diastereomers (1:1 ratio) signals could not be 
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uniquely identified and are thus identified as isomer 1 or 2. M.p. 144-145 
oC. 1H NMR (500.1 MHz, CDCl3, 25 
oC): δH 1.54 (d, 3 H, J = 7.0 Hz, 
CHMe isomer 1 or 2) overlapped by 1.55 (d, 3 H, J = 7.0 Hz, CHMe isomer 
1 or 2), 3.81 (s, 3 H, OMe, isomer 1 or 2) overlapped by 3.82 (s, 3 H, OMe, 
isomer 1 or 2), 4.67-4.75 (m, 2 H, CHMe both isomers), 6.06 (Ap, 1 H, JAq 
= 2.5 Hz, Cp isomer 1) overlapped by 6.08 (AB, 1 H, JAB = 2.5 Hz, Cp 
isomer 2), 6.29 (AB, 1 H, JAB = 2.5 Hz, Cp isomer 1) overlapped by 6.31 
(AB, 1 H, JAB = 2.5 Hz, Cp isomer 2), 6.43-6.46 (m, 2 H, Cp both isomers), 
6.72-6.76 (m, 2 H, Cp both isomers), 6.84-6.90 (m, 4 H, H-C(4) and H-C(6) 
Ar, both isomers), 6.94 (dd, 1 H, J = 7.0 Hz, 1.5 Hz, H-C(3) Ar, isomer 1 or 
2) overlapped by 6.95 (dd, 1 H, J = 7.0 Hz, 1.5 Hz, H-C(3) Ar, isomer 1 or 
2), 7.19 (ddd, 1 H, J = 7.0, 6.5, 1.0 Hz, H-C(5) Ar) overlapped by 7.20 
(ddd, 1 H, J = 7.0, 6.5, 1.0 Hz, H-C(5) Ar) 13C NMR (125.8 MHz, CDCl3, 
25 oC): δC 19.3 (CHMe both isomers), 34.5 (CHMe both isomer 1 or 2) 
overlapped by 34.5 (CHMe both isomer 1 or 2), 55.4 (OMe both isomers), 
110.9 (C(6) Ar both isomers), 116.3 (Cp isomer 1), 116.3 (Cp isomer 2), 
117.2 (Cp isomer 1), 117.4 (Cp isomer 2), 119.0 (Cp isomer 1), 119.4 (Cp 
isomer 2), 120.7 (C(3) or C(4) Ar both isomers), 121.8 (Cp isomer 2), 122.0 
(Cp isomer 1), 127.5 (C(5) Ar both isomers), 128.7 (C(3) or C(4) Ar both 
isomers), 134.6 (ipso-Cp both isomers), 142.2 (C(2) Ar isomer 1 or 2), 
142.5 (C(2) Ar isomer 1 or 2), 156.6 (C(1) Ar both isomers). IR (ATR):   = 
3110, 2936, 2834, 1598, 1586, 1491, 1461, 1437, 1421, 1366, 1334, 1290, 
1241, 1179, 1123, 1110, 1076, 1043, 1031, 986, 917, 861, 851, 827, 812, 
753, 706 cm-1. MS (MALDI TOF – DCTB matrix, 10% laser): m/z 481.1 
(M-Cl, 100%), 446.1 (M-2Cl, 29%). HRMS (ESI+) (M+Na+) Calcd. for 
C28H30Cl2O2TiNa
+ – 539.0995, found: 539.1004. CHN Anal. calcd. for 
C28H30Cl2O2Ti: C, 65.01; H, 5.85; found: C, 65.33; H, 6.14. 
 
Rac-dichloridobis(1-(phenyl)methyl-1’-(2-methoxyphenyl)-5-
cyclopentadienyl)titanium (9f): Prepared using 7f (707 mg, 2.70 mmol, 
1.0 equiv.), dry ether (10.8 mL) and n-BuLi (1.90 mL, 2.97 mmol, 1.1 
equiv.) yielding 8f (568 mg, 78% yield). This intermediate (2.12 mmol, 2.0 
equiv), then dissolved in 8.5 mL dry THF to give a colourless solution. 
Titanium tetrachloride (1.05 mmol, 1.05 mL, 1.0 equiv.) was dissolved in 
8.5 mL dry THF to give a yellow solution. Purification involved the 
dissolution of the crude red solid, 0.350 g (66%), in a saturated solution of 
chloroform (1 part) followed by layering of hexane (4 parts), giving red 
crystals of the rac-isomer of 9f (confirmed by X-ray data) with a yield 
(based on titanium) of (93.0 mg, 14% - based on titanium). The mother 
liquors ca. 50% contained a rac/meso mixture of 9f that could not be 
brought to a state of analytical purity despite repeted trials. M.p. 244-245 
oC. 1H NMR (500.1 MHz, CDCl3, 25 
oC): δH 3.67 (s, 6 H, 2 x OMe), 4.87 
(AB, 2 H, JAB = 2.5 Hz, Cp), 5.97 (br s, 2 H, CHPh), 5.99 (AB, 2 H, JAB = 
2.5 Hz, Cp), 6.42 (AB, 2 H, JAB = 2.5 Hz, Cp), 6.68 (dd, 2 H, J = 7.5, 1.5 
Hz, Ph), 6.76 (AB, 2 H, JAB = 2.5 Hz, Cp), 6.78-6.83 (m, 4 H, H-C(4) and 
H-C(6) Ar), 7.17 (dd, 1 H, J = 7.5 Hz, 1.5 Hz, H-C(3) Ar), 7.18-7.23 (m, 7 
H, Ph and Ar), 7.25 (br s, 2 H, Ph), 7.26-7.27 (m, 2 H, Ph), 7.27-7.28 (m, 1 
H, Ph). 13C NMR (125.8 MHz, CDCl3, 25 
oC): δC 45.9 (CHPh) 55.4 (OMe), 
110.3 (Cp), 110.8 (C(6) Ar), 116.0 (Cp), 120.0 (Ar), 123.7 (Cp), 126.6 (Ar 
or Ph), 127.9 (Ar or Ph) overlapped by 127.9 (Ar or Ph), 128.8 (Ph), 129.6 
(Ph or Ar), 131.8 (Cp), 132.7 (Ph), 140.5 (Ar or Ph), 141.5 (Ar or Ph), 
158.7 (C(1) Ar). IR (ATR):   = 3119, 2838, 1599, 1584, 1488, 1461, 1452, 
1436, 1341, 1319, 1290, 1246, 1187, 1162, 1008, 1075, 1058, 1050, 1029, 
953, 940, 898, 847, 837, 826, 794, 783, 765, 751, 735, 728, 700, 686 cm-1. 
MS (MALDI TOF – DCTB/NaI matrix, 25% laser): m/z 605.2 (M-Cl, 
100%), 570.2 (M-2Cl, 7%). HRMS (ESI+) (M+Na+) Calcd. for 
C38H34Cl2O2TiNa
+ – 663.1308, found: 663.1315. CHN Anal. calcd. for 
C39H36Cl4O2Ti (9f dichloromethane monosolvate from CH2Cl2/hexanes): C, 
64.49; H, 5.00; found: C, 64.61; H, 5.00. 
 
Dichloridobis-1-(2-methoxyphenyl)-5-cyclopentadienyl) titanium (10): 
Procedure as in literature.[11] The compound had properties identical to 
those in the primary literature (13C NMR, IR, MS, CHN analyses) but its 1H 
NMR specrum showed differences in the multiplicities of the C5H4 ‘Cp’ 
protons: 1H NMR (500.1 MHz, CDCl3, 22 
oC): δH 3.84 (s, 6.0 H, 2 x OMe), 
4.03 (s, 4 H, 2 x Cp-CH2), 6.33 (t, 4 H, J = 5.5 Hz, 2 x Cp), 6.40 (t, 4 H, J = 
5.0 Hz, 2 x Cp), 6.85-6.92 (m, 4 H, 2 x Ar), 7.16 (dd, 2 H, J = 7.5 Hz, 
1.5Hz, H-C(6’)), 7.23 (dt, 2 H, J = 7.5 Hz, 1.5 Hz, Ar).   
 
Growth inhibitory studies in vitro  
The antiproliferative activity was performed by MTT [3-(4, 5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay on three different 
human carcinoma cell lines; colon (HCT-116), pancreas (MiaPaCa-2), and 
breast (MDA-468). The carcinoma cell lines were maintained in RPMI 
1640 medium supplemented with 10% (v/v) FBS (foetal bovine serum).   
Cells were seeded into 96-well plates at a density of 3 x 103 per well (180 
µL per well) and allowed to adhere for 24 h at 37 OC / 5% CO2. A 10 mM 
top stock solution in DMSO was then freshly made. Serial dilutions were 
prepared in RMPI 1640 medium supplemented with 10% FBS. Control 
wells recieved vehicle alone (20 µL per well). The final concentrations in 
the wells were; 0.01 µM, 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM and 
100 µM. The final concentration of DMSO in the wells never exceded 1%. 
Vehicle control assays were performed (0.0001 – 1% DMSO) Experimental 
plates were incubated for a further 72 h period at 37 oC / 5% CO2. Cell 
viability was recorded at the time of agent addition (T0) and following 72 h 
exposure: following addition of  MTT solution (2 mg/mL in PBS - 50 µL 
per well), experimental plates were incubated for 3 h to allow reduction of 
MTT to insoluble dark purple formazan crystals. The supernatant in each 
well was then aspirated and cellular formazan solublised by addition of 
DMSO (150 µL per well). Absorbance was read at a wavelength of 550 nm 
using an Anthos Labtec systems plate reader. Measured intensity is 
proportional to metabolic activity which correlates to cellular viability. 
Agent GI50 values (the concentration of agent which inhibits growth by 
50%) were calculated by performing MTT assays at time of drug addition 
as well as after 72 h exposure.   
 
Supporting Information 1H and 13C NMR spectra for all compounds 
prepared in this study. 
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